Delcath Systems (NASDAQ:DCTH) Cut to Hold at Wall Street Zen

Delcath Systems (NASDAQ:DCTH) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

DCTH has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $29.00 target price (up from $24.00) on shares of Delcath Systems in a research report on Friday, May 23rd. Stephens reaffirmed an “overweight” rating and set a $25.00 price objective on shares of Delcath Systems in a research report on Monday, June 23rd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Delcath Systems presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Delcath Systems Stock Up 1.7%

Shares of Delcath Systems stock opened at $12.73 on Friday. Delcath Systems has a twelve month low of $7.17 and a twelve month high of $18.23. The company has a 50-day simple moving average of $14.75 and a two-hundred day simple moving average of $13.79. The stock has a market capitalization of $443.21 million, a price-to-earnings ratio of -25.45 and a beta of 0.87.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.07). The company had revenue of $19.80 million during the quarter, compared to the consensus estimate of $16.83 million. Delcath Systems had a negative net margin of 26.38% and a negative return on equity of 29.44%. On average, sell-side analysts anticipate that Delcath Systems will post -0.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Delcath Systems

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quarry LP bought a new stake in Delcath Systems during the fourth quarter worth $34,000. Quantbot Technologies LP bought a new stake in shares of Delcath Systems during the 4th quarter worth $66,000. Inlight Wealth Management LLC bought a new stake in shares of Delcath Systems during the 1st quarter worth $85,000. NBC Securities Inc. lifted its position in shares of Delcath Systems by 99,900.0% during the 1st quarter. NBC Securities Inc. now owns 10,000 shares of the company’s stock worth $127,000 after buying an additional 9,990 shares during the last quarter. Finally, Graham Capital Management L.P. bought a new position in shares of Delcath Systems in the fourth quarter worth about $123,000. 61.12% of the stock is currently owned by institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.